17 May 2025 - 18 May 2025
08:00 AM - 09:00 PM
6th Knowledge Series for Genitourinary Cancers - Best of 2024
Program Director: Chairpersons: Dr. N P Gupta, Gurugram (UO) Dr. Amlesh Seth, Delhi (UO) Dr. Nitin Kekre, Vellore (UO), Dr. V Kannan, Mumbai (RO)
Day 1
Date : 17 May 2025
| AI vs Radiologists in Prostate Cancer Detection: Insights from the PI-CAI International Study. | 09:00 AM - 09:10 AM |
| 10-Year Trial: Laparoscopic vs Robot-Assisted Radical Prostatectomy Outcomes | 09:10 AM - 09:17 AM |
| MRI vs PSMA-PET: Predicting Prostate Cancer Extension & Surgical Guidance Trial | 09:17 AM - 09:24 AM |
| Radical Prostatectomy Without Biopsy: Insights from PSMA-PET/CT & MRI Trial | 09:24 AM - 09:31 AM |
| Phase 3 Trial: Stereotactic Body Radiotherapy in Localized Prostate Cancer (NEJM 2024) | 09:31 AM - 09:38 AM |
| Hypo-FLAME Trial: 5-Year Outcomes of SBRT with Focal Boost in Prostate Cancer (2024) | 09:38 AM - 09:45 AM |
| HYPO-RT-PC Trial: Long-Term Morbidity After Prostate Ultra-Hypofractionation | 09:45 AM - 09:52 AM |
| Panel Discussion: Key Insights from Recent Prostate Cancer Clinical Trials & Studies | 10:00 AM - 10:30 AM |
| Pelvic Lymph Node Dissection in Prostate Cancer: Limited vs Extended Trial Update | 10:40 AM - 10:47 AM |
| Trifecta Outcomes with 3D Digital Models in Robotic Prostatectomy: Trial Analysis | 10:47 AM - 10:57 AM |
| RE-START Study: Re-SBRT After Definitive or Salvage Radiotherapy in Prostate Cancer | 10:57 AM - 11:04 AM |
| PACE-A Trial: Radical Prostatectomy vs Stereotactic Radiotherapy in Localised Prostate Cancer | 11:04 AM - 11:11 AM |
| ASCO-GU 2025: Radical Prostatectomy vs Radiotherapy in High-Risk Prostate Cancer (IPD Study) | 11:11 AM - 11:18 AM |
| ESMO 2024: Transdermal Estradiol vs LHRH Agonists in M0 Prostate Cancer (Phase 3 Trial) | 11:18 AM - 11:25 AM |
| PARTIQoL Trial: Proton Therapy vs IMRT in Localized Prostate Cancer (Phase III Results) | 11:25 AM - 11:32 AM |
| PORTOS Gene Signature: Predicting Dose-Response to Prostate Radiation in Phase III Trials | 11:32 AM - 11:42 AM |
| Panel Discussion: Advances & Insights from Recent Prostate Cancer Trials and Research | 11:45 AM - 12:15 PM |
| Darolutamide + ADT in Metastatic Hormone-Sensitive Prostate Cancer: Phase III ARANOTE Trial. | 12:25 PM - 12:32 PM |
| ASCO GU 2025: STOPCAP Meta-Analysis on AR Pathway Inhibitors in mHSPC Patients | 12:32 PM - 12:39 PM |
| ASCO 2024: PLATIPARP Trial – Induction Chemo + Rucaparib in HRR-Deficient mCRPC | 12:39 PM - 12:46 PM |
| ASCO GU 2025: Docetaxel Rechallenge vs Cabazitaxel in Previously Treated mCRPC Patients | 12:46 PM - 12:53 PM |
| ASCO GU 2025: Extended Interval Dosing of Denosumab in Metastatic Prostate Cancer Patients | 12:53 PM - 01:00 AM |
| ENZA-p Trial: [177Lu]Lu-PSMA-617 + Enzalutamide vs Enzalutamide in mCRPC – Survival & QoL | 01:00 AM - 01:10 AM |
| ASCO GU 2025: Exercise Program to Reduce Fatigue in Advanced Prostate Cancer on ADT | 01:10 AM - 01:17 AM |
| ASCO GU 2025: GROUQ-PCS9 Trial – Metastases-Directed Therapy in Oligometastatic mCRPC | 01:17 AM - 01:24 AM |
| Panel Discussion: Key Insights on Prostate Cancer Clinical Trials & Abstracts | 01:40 AM - 02:10 AM |
| Enfortumab Vedotin in Relapsed/Refractory Bladder Cancer: Clinical Outcomes & Advances | 02:50 AM - 03:20 AM |
| Phase 3 Trial: [89Zr]Zr-Girentuximab PET-CT Imaging in Clear-Cell Renal Cell Carcinoma | 03:20 AM - 03:27 AM |
| Cryoablation vs Robotic Partial Nephrectomy in cT1 Renal Tumors: Systematic Review & Meta-Analysis | 03:27 AM - 03:34 AM |
| Positive Surgical Margins in Localized Renal Cell Carcinoma: Predictors & Survival Impact | 03:34 AM - 03:41 AM |
| Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival Outcomes (NEJM Study) | 03:41 AM - 03:48 AM |
| Panel Discussion: Key Advances in Renal Cell Carcinoma from Recent Clinical Trials & Studies | 04:00 AM - 04:30 AM |
| Upfront vs Deferred Cytoreductive Nephrectomy in Metastatic RCC: Systematic Review & Meta-Analysis | 05:40 AM - 05:47 AM |
| ASCO GU 2025: SABR with TKI & IO Therapy in Metastatic Renal Cell Carcinoma – Efficacy & Safety | 05:47 AM - 05:54 AM |
| ASCO GU 2025: CALYPSO Trial – Final OS & ctDNA Analysis in MET-Driven Papillary Renal Cancer | 05:54 AM - 06:01 AM |
| RENOTORCH Phase III: Toripalimab + Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma | 06:01 AM - 06:08 AM |
| CheckMate 9ER: Extended Follow-Up of Nivolumab + Cabozantinib vs Sunitinib in Advanced RCC | 06:08 AM - 06:15 AM |
| CheckMate 214: 8-Year Follow-Up of Nivolumab + Ipilimumab vs Sunitinib in Advanced RCC | 06:15 AM - 06:22 AM |
| Panel Discussion: Long-Term Immunotherapy & Targeted Therapy Advances in Renal Cell Carcinoma | 06:25 AM - 06:50 AM |
| Case-Based Panel: Peri-Operative Immunotherapy in Muscle-Invasive Bladder Cancer (MIBC) | 06:50 AM - 07:20 AM |
| CAR-T Cell Therapy: Advances, Applications & Future Directions in Cancer Treatment | 07:20 AM - 07:35 AM |
| Conquering Challenging Cases in mCSPC & mCRPC: Expert Insights in Prostate Cancer Care | 07:35 AM - 07:55 AM |
| Panel Discussion: Role of Patient Advocacy in Improving Life & Quality for Bladder Cancer Patients | 07:55 AM - 08:15 AM |
DAY 2
Date : 18 May 2024
| MRI vs TURBT for Staging New Bladder Cancer: Insights from the BladderPath Trial | 09:00 AM - 09:07 AM |
| Bladder-Sparing Therapy vs Radical Cystectomy: Long-Term Outcomes in BCG-Unresponsive NMIBC | 09:07 AM - 09:17 AM |
| Bladder-Sparing Therapy in BCG-Unresponsive NMIBC: IBCG Recommendations on Sequencing & Patient Selection | 09:17 AM - 09:24 AM |
| Bladder-Preserving Trimodality Therapy for High-Grade T1 Bladder Cancer: NRG/RTOG 0926 Results | 09:24 AM - 09:31 AM |
| NIAGARA Phase 3 Trial: Neoadjuvant Durvalumab + Chemo & Adjuvant Durvalumab in MIBC | 09:31 AM - 09:38 AM |
| Phase II RC48-C017: Disitamab Vedotin + Toripalimab as Neoadjuvant Therapy in HER2+ MIBC | 09:38 AM - 09:45 AM |
| Variant Histology in NMIBC: Impact on Upstaging & Survival After Radical Cystectomy | 09:45 AM - 09:52 AM |
| BCG vs Gemcitabine + Docetaxel for Treatment-Naïve Intermediate-Risk NMIBC: Comparative Study | 09:52 AM - 09:59 AM |
| BART Trial: Acute & Late Toxicity of Adjuvant Radiation in Bladder Cancer (Phase III RCT) | 09:59 AM - 10:06 AM |
| Hypofractionated Chemoradiotherapy for Bladder Preservation in MIBC: Results from ESTRO 2024 | 10:06 AM - 10:16 AM |
| Panel Discussion: Advances in Bladder Cancer Care from ESTRO & ASTRO 2024 Clinical Abstracts | 10:25 AM - 10:55 AM |
| Exploring First-Line Strategies in Metastatic Urothelial Carcinoma | Insights from CheckMate 901 | 11:00 AM - 11:20 AM |
| Pembrolizumab After Tri-Modality Therapy in Muscle-Invasive Bladder Cancer | ASTRO 2024 Insights | 12:00 PM - 12:07 PM |
| Neoadjuvant Chemotherapy Before Chemoradiotherapy in Muscle-Invasive Bladder Cancer | Meta-Analysis Insights | 12:07 PM - 12:17 PM |
| ASCO GU 2025: Neoadjuvant Durvalumab + Chemo in High-Risk Upper Tract Urothelial Carcinoma | 12:17 PM - 12:22 PM |
| POUT Trial Final Results: Adjuvant Chemotherapy Boosts DFS After Nephroureterectomy in UTUC | 12:22 PM - 12:27 PM |
| TOMBOLA Trial: ctDNA-Guided Early Post-Cystectomy Immunotherapy in Bladder Cancer Patients | 12:27 PM - 12:34 PM |
| Enfortumab Vedotin + Pembrolizumab: First-Line Breakthrough in Advanced Urothelial Cancer | 12:34 PM - 12:44 PM |
| Panel Discussion: Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Cancer | 12:55 PM - 01:20 AM |
| ARASENS Subgroup Analysis & Key ASCO GU 2025 Updates in Prostate Cancer Research | 01:30 AM - 01:50 AM |
Program Director:
Chairpersons: Dr. N P Gupta, Gurugram (UO) Dr. Amlesh Seth, Delhi (UO) Dr. Nitin Kekre, Vellore (UO), Dr. V Kannan, Mumbai (RO)
Contact Person
Undisclosed
genitourinarycancers@gmail.com
+91-0000000000
Download